Lisata Therapeutics Inc.
01/21/2026 | Press release | Distributed by Public on 01/21/2026 08:20
Washington, D.C. 20549 (Form SC14D9C)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
LISATA THERAPEUTICS, INC.
(Name of Subject Company)
LISATA THERAPEUTICS, INC.
(Name of Person Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
128058302
(CUSIP Number of Class of Securities)
David J. Mazzo, Ph.D.
Chief Executive Officer
Lisata Therapeutics, Inc
110 Allen Road, Second Floor
Basking Ridge, NJ 07920
(908) 841-0100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
Jeffrey P. Schultz, Esq.
Daniel A. Bagliebter, Esq.
Mintz Levin Cohn Ferris Glovsky & Popeo, P.C.
919 Third Avenue
New York, NY 10022
(212) 935-3000
|
☒
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Lisata Therapeutics, Inc. on January 21, 2026 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.
Lisata Therapeutics Inc. published this content on January 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on January 21, 2026 at 14:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]